Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.

[1]  J. Johansson,et al.  Cancer incidence in healthy Swedish peripheral blood stem cell donors , 2022, Bone Marrow Transplantation.

[2]  Stephanie J. Lee,et al.  Three FDA-approved therapies for chronic GVHD. , 2022, Blood.

[3]  N. Kröger,et al.  Steroid-refractory chronic graft-versus-host disease: treatment options and patient management , 2021, Bone Marrow Transplantation.

[4]  G. Cuvelier,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report , 2021, Transplantation and cellular therapy.

[5]  J. Ritz,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. , 2021, Transplantation and cellular therapy.

[6]  M. Grce,et al.  Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease , 2020, Frontiers in Immunology.

[7]  Ying Zhang,et al.  High proportions of CD3+ T cells in grafts delayed lymphocyte recovery and reduced overall survival in haploidentical peripheral blood stem cell transplantation. , 2020, Molecular and clinical oncology.

[8]  R. Maziarz,et al.  Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors. , 2019, Cytotherapy.

[9]  T. Spitzer,et al.  Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. , 2019, Transfusion medicine reviews.

[10]  J. Irish,et al.  Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies , 2018, Haematologica.

[11]  E. Weissinger,et al.  Biomarkers in chronic graft-versus-host disease: quo vadis? , 2018, Bone Marrow Transplantation.

[12]  Jian-zhu Yang,et al.  Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant. , 2017, Cellular immunology.

[13]  M. Arora,et al.  Evolving concepts in prognostic scoring of chronic GvHD , 2017, Bone Marrow Transplantation.

[14]  G. Hill,et al.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. , 2017, Blood.

[15]  J. Partanen,et al.  Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML , 2016, Front. Immunol..

[16]  E. Weissinger,et al.  Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments , 2016, Front. Immunol..

[17]  W. Wood,et al.  Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  P. Campregher,et al.  Survival and graft‐versus‐host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA‐matched related donor: retrospective analysis of 334 consecutive patients , 2015, European journal of haematology.

[19]  Y. Tanhehco,et al.  Defining the quality of hematopoietic stem cell products: the devil is in the details , 2015, Transfusion.

[20]  P. Ljungman,et al.  Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation , 2015, Transfusion.

[21]  D. Porter,et al.  High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Theurich,et al.  Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis. , 2015, Critical reviews in oncology/hematology.

[23]  M. Remberger,et al.  Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  R. Vij,et al.  Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  B. Storer,et al.  Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease , 2014, Haematologica.

[27]  B. Shaw,et al.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. , 2014, Blood.

[28]  J. Miguel,et al.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease , 2012, Haematologica.

[29]  G. Specchia,et al.  CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  J. Perkins,et al.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality , 2011, Haematologica.

[31]  J. Pagel,et al.  HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  D. Miklos,et al.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation , 2010, Proceedings of the National Academy of Sciences.

[33]  K. Ness,et al.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. , 2005, Blood.

[34]  R. Negrin,et al.  CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. , 2005, Experimental Hematology.

[35]  John P Klein,et al.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.

[36]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[37]  W. Krüger,et al.  A randomized comparison of once versus twice daily recombinant human granulocyte colony‐stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation , 2000, British journal of haematology.

[38]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[40]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.